High prescribing and state-level variation in z-drug use among Medicare patients

Kaitlin E. Anderson¹, James L. Basting¹, Rachel I. Gifeisman¹, Donovan J. Harris¹, Antonica R. Rajan¹, Kenneth L. McCall², Brain J. Piper^{1,3*}

¹Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA

²Department of Pharmacy Practice, University of New England, Portland, ME

³Center for Pharmacy Innovation & Outcomes, Forty Fort, PA

*psy391@gmail.com, bpiper@som.geisinger.edu, ORCID: 0000-0002-2295-445X

Submission type: original research

Abstract: 248 / 250 words

Manuscript:

Figures: 4, Tables: 0, Supplemental Materials: 1 Fig

Competing Interests: BJP was part of an osteoarthritis research team from 2019-2021 supported by Pfizer and Eli Lilly. The other authors have no disclosures.

Acknowledgements: BJP was supported by the Health Resources Services Administration (D34HP31025). Software used in this effort was provided by the NIEHS (T32- ES007060-31A1). Iris Johnston provided technical support.

Data: A preprint with raw data was submitted to MedRxiv at 5/11/2022. Original data is also available at: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Part-D-Prescriber

Abstract

Background: Z-drugs are nonbenzodiazepine hypnotics used for sleep initiation and maintenance that have been shown to increase the risk of fall-related injuries in patients aged 65 and older. The American Geriatrics Society Beers criteria classifies them as a high-risk medication and strongly recommends avoiding prescribing z-drugs to the elderly due to adverse effects. The objective of this study was to determine the prevalence of Z-drug prescribing among Medicare patients. Methods: Z-drug prescription data was extracted from the Centers for Medicare and Medicaid Services State Drug Utilization Data (CMS SDUD) for 2018. For all 50 states, the number of prescriptions per 100 Medicare enrollees and days-supply per prescription was determined. The percentage of total prescriptions prescribed by each specialty and the average number of prescriptions prescribed by providers within each specialty was also determined. Results: Zolpidem was the most prescribed z-drug, making up 95.0% of all z-drug prescriptions. Prescriptions per 100 enrollees were significantly elevated in Utah (28.2) and Arkansas (26.7) and significantly lower in Hawaii (9.3) relative to the national average (17.5). The specialties family medicine (32.1%), internal medicine (31.4%), and psychiatry (11.7%) made up the largest percentages of total prescriptions. The number of prescriptions per provider was significantly elevated for psychiatry relative to other specialties. Conclusions: Contrary to the Beers criteria, z-drugs are being prescribed to Medicare enrollees over age 65 at high rates. While sleep disturbances in the elderly should not be ignored, alternative therapies must be considered to avoid the serious adverse effects of z-drugs.

Key Points

More than one-half million Medicare patients received z-drug prescriptions in 2018 that were inconsistent with the Beers criteria.

Z-drug prescriptions per 100,000 Medicare patients were significantly elevated in Utah and Arkansas.

Family Medicine had the highest number of prescriptions out of all medical specialties.

Psychiatry had a significantly higher number of prescriptions per provider compared to all other specialties.

Introduction

Over one-third (35%) of the US population experiences short sleep, less than 7 hours [1]. Up to 50% of people over 60 years report sleep disorder symptoms while 12-20% of the elderly were diagnosed with insomnia disorder [1]. Symptoms include difficulty initiating and maintaining sleep, fatigue, mood disturbances and impaired daytime performance [2]. The elderly are considered a "special population" as they are at an increased risk for adverse drug effects and comorbidities including heart disease, stroke, diabetes, depression, and cancer [3].

Nonbenzodiazepine hypnotics zolpidem, zaleplon, zopiclone, and eszopiclone, commonly referred to as 'z-drugs' represent a large class of sedatives which are approved for sleep initiation and maintenance. While most z-drugs act as a selective agonist at the GABA_A $\alpha 1$ subunit, zopiclone and eszopiclone are non-selective and bind to the α_1 , α_2 , α_3 and α_5 subunits (i.e., the same mechanism as benzodiazepines) [4]. Z-drugs have been shown to increase the risk of fall-related injuries, such as fractures and traumatic brain injuries, in elderly patients [5]. Additionally, withdrawal symptoms for these Schedule IV drugs include delirium, which can potentiate the risk of fall-related injuries. These adverse effects are reflected in the American Geriatrics Society (AGS) Beers criteria guidelines for these drugs, which made a strong recommendation in 2019 to avoid prescribing z-drugs to patients 65 years and older. Interestingly, the AGS also reports that z-drugs provide only minimal improvement in sleep duration and latency in the elderly [6]. Similarly, Kaiser-Permanente considers z-drugs as not safer for older adults than benzodiazepines and are a "high-risk medication in the elderly" [7].

Therefore, it is important to track the prescription patterns of these drugs to patients aged 65 or older in the United States. This study provides a nationwide examination of z-drug prescriptions to Medicare enrollees in 2018.

Methods

Procedures: Medicare Part D data was acquired from the Centers for Medicare and Medicaid Services State Drug Utilization Data (CMS SDUD) for 2018 [8]. Both generic and name brand formulations of z-drugs were considered for analysis (zolpidem, Ambien, Edluar, Intermezzo, Zolpimist, eszopiclone, Lunesta, zopiclone, zaleplon, and Sonata, Supplemental Table 1).

Data-analysis: For each state, z-drug prescriptions were summed and divided by the number of Medicare enrollees in that state, as reported by the CMS. This data was normalized and reported as the number of Z-drug prescriptions per 100 Medicare enrollees. States that were $\geq \pm 1.96$ standard deviations outside the mean were categorized as statistically significant (p < .05). An exploratory correlation was completed between percent obesity in 2018 [9] and prescriptions per state. Additionally, the total days' supply was divided by the total number of prescriptions for each state and reported as days-supply per prescription. An analysis of providers prescribing z-drugs was also performed. Prescriber data was obtained from the Medicare Part D Prescriber Dataset from CMS [8]. Using a python script (Supplemental Appendix 2), the sum of the total claim counts for each specialty was calculated and used to determine the percentage of all z-drug prescriptions prescribed by each specialty. Additionally, the total number of z-drug prescriptions within each specialty with greater than 100 providers was divided by the number of providers within that specialty as reported in CMS. Specialties with a prescriptions-per-provider value ≥ 1.96 standard deviations outside the mean were identified as statistically significant (p < .05).

Results

Overall, zolpidem accounted for the vast preponderance (95.0%) of z-drug prescriptions. Additionally, generic formulations made up 99.7% of prescriptions.

The average number prescriptions per 100 Medicare enrollees was 17.5 ± 4.0 . There was a three-fold (3.04) difference between the highest and lowest states. Utah (28.2) and Arkansas (26.7) were significantly elevated, and Hawai'i (9.3) was significantly lower relative to the state mean (Figure 1). States with higher levels of obesity also had significantly more prescriptions (r(49) = +0.35, p < .05, Figure 2).

The average days-supply per prescription was 34.9. Delaware (40.2) was significantly longer, and New York (29.3) was significantly shorter than the national mean (Supplemental Figure 1). States with more prescriptions per enrollee tended to have shorter days' supply but this was not significant (r(51) = 0.26, p = .063).

Three medical specialties comprised three-quarters (75.2%) of all z-drug prescriptions in 2018. Family Medicine (2,351,301, 32.1%) had the highest number of prescriptions followed by internal medicine (2,298,487, 31.4%) and psychiatry (853,649, 11.7%). All other specialties combined comprised 24.8% (Supplemental Figure 2). The average number of z-drug prescriptions per provider was 40.3 ± 12.1 . Psychiatry was significantly elevated relative to the average with 76.5 prescriptions per provider (Figure 3).

Discussion

It is clear Medicare patients are being prescribed z-drugs, predominantly zolpidem, at high rates despite clear guidelines to avoid use of these drugs in the elderly by the AGS due to the increased risk of adverse effects including fractures from falls, stroke, and psychological distress [6]. While elderly patients are being prescribed these drugs nationwide, there also appears to be substantial state level differences in z-drug prescriptions. We are skeptical that the identified three-fold difference between states in prescribing rates is matched by a three-fold difference in the prevalence of sleep problems. We also found a low, but significant, correlation (r = .33) between the prevalence of obesity and the z-drug prescribing rate. Obesity is a contributor to sleep apnea, and this can result in complaints to prescribers of unsatisfactory sleep quality. A systematic review identified some evidence that eszopiclone could improve continuous positive airway pressure adherence [10]. Utah and Arkansas had significantly elevated z-drug prescriptions per 100 Medicare enrollees. Meanwhile, Hawaii had the lowest number of z-drug prescriptions per 100 Medicare enrollees. This is consistent with other data showing that Hawaii also has the lowest rates of opioid and antibiotic prescriptions [11, 12]. Potential explanations for this include that Hawaii is among the healthiest states when ranked by rates of obesity, insurance coverage, and numbers of preventable hospitalizations [13]. Additionally, the large Asian population is more likely to be skeptical of prescription drugs – opting instead for increased familial support and alternative medicine [14]. However, more research is necessary to understand which factors are most influential in keeping Hawaii's z-drug prescriptions low, as well as why Arkansas and Utah's prescriptions are so comparatively high.

In the analysis of z-drug prescriptions per specialty; family medicine, internal medicine, and psychiatry took the largest share of prescriptions. The predominance of family medicine and internal medicine over psychiatry may be explained by patients with sleep problems presenting more often to their primary care physician rather than a specialist provider [15]. This disparity may also be influenced by only about 23% of US psychiatrists being covered by Medicare [16]. However, it did not escape notice that one hundred percent of the working group for the American Psychiatric Association's Diagnostic and Statistical Manual for Sleep/Wake Disorders had ties to the pharmaceutical industry which raises concerns about further relaxation of the diagnostic criteria in future revisions of the DSM-5-TR [17]. Other studies have documented general practitioners (GPs) mixed perspectives on z-drug prescription, noting that many GPs experienced tension between their desire to help patients with insomnia and their fear of contributing to over-prescription of drugs with such potentially severe adverse effects [18].

It is important to emphasize that, as of 2018, less than 10% of Medicare patients were less than age 65 [19]. In addition, less than 3% of Medicare enrollees received hospice care in 2018 [20]. Based on the volume and duration of prescriptions, more than one-half million Medicare enrollees received z-drug prescriptions in 2018 that were inconsistent with the Beers Criteria. Further research with other databases including electronic health records will be necessary to identify additional subsets of Medicare patients where guidelines were not applicable, as well as determination of patient subgroups (e.g., nursing home residents and those who are obese) at greatest risk of receiving potentially inappropriate z-drug prescriptions.

Conclusion

Sleep disorders in the elderly remain a significant problem and should not be ignored. Considering that guidelines in the United States state z-drug use is contraindicated in the elder population due to the risk of adverse events, especially falls, it is important to begin implementing changes in prescription practices such as utilizing alternative therapies. Some treatment options that have proven successful include cognitive behavior therapy or the development of consistent, healthy sleeping habits. Perhaps more drastic measures may be appropriate if patients remain symptomatic, but alternative therapies should certainly be attempted initially. Further research is needed to ascertain exactly whether these alternative therapies are not being initiated and why regional differences exist in number of prescriptions of z-drugs per individual prescribers.

- 1. Patel D, Steinberg J, Patel P. Insomnia in the elderly: A review. J Clin Sleep Med. 2018;14(6):1017-24.
- Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. *Chest*. 2014;146(5):1387-94.
- 3. Foley DJ, Monjan A, Simonsick EM, Wallace RB, Blazer DG. Incidence and remission of insomnia among elderly adults: An epidemiologic study of 6,800 persons over three years. *Sleep*. 1999;22 Suppl 2:S366-72.
- 4. Stahl SM. *Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications*. 5th ed. Cambridge, England: Cambridge University Press; 2021.
- 5. Treves N, Perlman A, Kolenberg Geron L, Asaly A, Matok I. Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis. *Age Ageing*. 2018;47(2):201-8.
- 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American geriatrics society 2019
 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc*.
 2019;67(4):674-694.
- 7. Benzodiazepine and z-drug safety guideline [Internet]. Kaiser Permanente; 2022 [cited 2022 Mar 13]. 29 p. Available from: https://wa.kaiserpermanente.org/static/pdf/public/guidelines/benzo-zdrug.pdf
- 8. Medicare provider utilization and payment data: Part D Prescriber [Internet]. Cms.gov. [cited 2022 Mar 13]. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Part-D-Prescriber
- 2018 BRFSS survey data and documentation [Internet]. Cdc.gov. 2019 [cited 2022 May 1]. Available from: https://www.cdc.gov/brfss/annual_data/annual_2018.html
- 10. Wang D, Tang Y, Chen Y, Zhang S, Ma D, Luo Y, Li S, Su X, Wang X, Liu C, Zhang N. The effect of non-benzodiazepine sedative hypnotics on CPAP adherence in patients with OSA: A systematic review and meta-analysis. *Sleep*. 2021;44(8): zsab077.
- 11. Hawaii opioid summary [Internet]. National Institute on Drug Abuse. 2019 [cited 2022 Mar 13]. Available from: https://nida.nih.gov/sites/default/files/21954-hawaii-opioid-summary.pdf
- 12. Arizpe A, Reveles KR, Aitken SL. Regional variation in antibiotic prescribing among Medicare part D enrollees, 2013. *BMC Infect Dis*. 2016;16(1):744.

- 13. Explore health measures in Hawaii [Internet]. America's Health Rankings. [cited 2022 Mar 13]. Available from: https://www.americashealthrankings.org/explore/annual/state/HI
- 14. Jones RG. Live in Hawaii, and odds are you'll need fewer prescription meds. NPR [Internet]. 2017 Aug 31 [cited 2022 Mar 13]; Available from: https://www.npr.org/sections/health-shots/2017/08/31/547317533/ornstein-it-s-better-in-hawaii
- 15. Abed Faghri NM, Boisvert CM, Faghri S. Understanding the expanding role of primary care physicians (PCPs) to primary psychiatric care physicians (PPCPs): Enhancing the assessment and treatment of psychiatric conditions. *Ment Health Fam Med.* 2010;7(1):17-25.
- 16. McGinty B. Medicare's mental health coverage: How COVID-19 highlights gaps and opportunities for improvement [Internet]. Commonwealth Fund; 2020 [cited 2022 Mar 13]. Available from: https://www.commonwealthfund.org/publications/issue-briefs/2020/jul/medicare-mental-health-coverage-covid-19-gaps-opportunities
- 17. Cosgrove L, Krimsky S. A comparison of DSM-IV and DSM-5 panel members' financial associations with industry: A pernicious problem persists. *PLoS Med*. 2012;9(3):e1001190.
- Sirdifield C, Anthierens S, Creupelandt H, Chipchase SY, Christiaens T, Siriwardena AN. General practitioners' experiences and perceptions of benzodiazepine prescribing: Systematic review and metasynthesis. *BMC Fam Pract*. 2013;14:191.
- 19. Data Analysis Brief: Medicare-Medicaid dual enrollment 2006 through 2018 [Internet]. CMS Medicare-Medicaid Coordination Office. 2019 [cited 2022 Mar 13]. Available from: <a href="https://www.cms.gov/Medicare-Medicaid-Coordination/Medicare-Medicaid-Coordination-Medicaid-Coordination-Medicaid-Coordination-Medicare-Medicaid-Coordination-Medicaid-
- NHPCO Facts and Figures [Internet]. National Hospice and Palliative Care Organization. 2020 [cited 2022
 Mar 13]. Available from: https://www.nhpco.org/hospice-facts-figures/

Figure 1. Z-drug prescriptions per 100 Medicare enrollees ranked by state. States with a * are \geq 1.96 SD and # were \geq 1.50 SD.




Figure 2. Scatterplot showing significant association between percent obesity and Z-drug prescriptions Medicare patients per state ($R^2(49) = .106$, p = .02).






Figure 3. Z-drug prescriptions by specialty to Medicare patients in 2018. * are \geq 1.96 SD and # were \geq 1.50 SD.



Supplemental Figure 1. Z-drug days supply per prescription to Medicare enrollees by state.



Drug	NDCs
Zolpidem	0093-0073
	0093-0074
	0615-8225
	0615-8226
	0781-5315
	0781-5316 0781-5317
	0781-5317
	0904-6082
	0904-6083
	0955-1702
	0955-1703
	10370-116
	10370-117
	13668-007
	13668-008 16714-621
	16714-622
	40032-761
	40032-762
	42291-963
	42291-964
	43063-639
	43063-652
	43353-242 43353-243
	43353-243
	43386-761
	43386-762
	45865-409
	45865-413
	45865-956
	47335-307
	47335-308 49884-898
	49884-899
	49884-903
	49884-904
	50090-1022
	50090-1023
	50090-3878
	50090-3879
	50090-3994
	50090-4479 50090-5095
	50090-5096
	51407-554
	51407-555
	51991-981

51991-982
53002-1292
53002-5020
55111-478 55111-479
55154-1398
55700-268
55700-357
55700-573
55700-777
60760-288
60760-515 60760-531
61919-449
61919-663
61919-812
63187-114
63187-558
63187-565
63187-682 63187-690
63187-691
63187-707
63187-862
63629-1171
63629-3549
63629-4708
63629-7795 63629-8163
63629-8998
63629-8999
63739-526
65862-159
65862-160
67296-1591
68071-1887 68071-1895
68071-2232
68071-2354
68071-2450
68071-4598
68071-5063
68071-5093
68071-5120 68071-5255
68084-189
68180-779
68180-780
68788-7407
68788-7422
68788-7688

	68788-7903
	68788-8118
	68788-9126
	68788-9127
	70518-1663
	70518-2865
	70518-2917
	70934-453
	70934-700
	70934-917
	71093-155
	71093-156 71205-286
	71335-0154
	71335-0134
	71335-0203
	71335-1468
	71335-1801
	71610-151
	71610-152
	71610-156
	71610-192
	71610-254
	71610-272
	71610-273
	71610-564
	72189-230
	80425-0059
	80425-0060
	80425-0061 80425-0087
	80425-0067
	80425-0155
Amblen	0024-5401
Allibiell	0024-5401
	61919-803
	61919-948
	0024-5501
	0024-5521
	55289-205
Edluar	0037-6010
	0037-6050
Intermezzo	59011-255
	59011-256
Zolpimist	69654-510
Eszopicione	0093-5537
	0093-5538
	0093-5539
	0378-5270
	0378-5271

0378-5272
33342-299
33342-300
33342-301
42043-320
42043-321
42043-322
43063-795
43353-097
43353-101 43353-185
43353-200 45865-828
45865-829
45865-830
47335-586
47335-587
47335-588
50090-3514
50090-3553
50090-3989
50090-4202
50090-5084
50436-3383
50436-3384
55111-617
55111-619
55111-629
55700-581
55700-610
55700-621
60429-632
60429-633
60429-634
60760-325
60760-511
60760-526
61919-033
61919-119
61919-119 61919-395
61919-393
61919-402
61919-514
61919-587
61919-991
63187-579
63187-665
63187-817
63187-843
63187-970

	63629-5319
	65862-967
	65862-968
	65862-969
	68071-2403 68071-3376
	68180-322
	68180-323
	68180-324
	68462-382
	68462-383
	68462-384
	68788-6953
	68788-7029
	68788-7169
	68788-7667
	68788-8077 70518-1310
	70518-2979
	71205-236
	71205-384
	71205-513
	71205-581
	71205-633
	71335-0005
	71335-0089
	71335-0116
	71335-0148
	71335-0512 71335-0574
	71335-0598
	71335-1662
	71335-1794
	71335-2002
	71610-409
	72189-099
	72789-067
	76420-024
	76420-026
	76420-027
	80425-0062
	80425-0063 80425-0064
	80425-0065
	80425-0066
	80425-0067
	80425-0098
	80425-0115
	80425-0168
Lunesta	55289-014
	63402-190

	63402-191
	63402-193
Zalepion	0054-0084
	0054-0085
	29300-131
	29300-132
	42043-210
	42043-211
	43063-505
	43063-783
	43063-912
	45865-541
	50090-1564
	57237-239
	57237-240
	63629-3405
	65862-214
	65862-215
	68788-7208
	71335-0236
	71335-1054
	71335-1387
Sonata	54868-4431
	54868-5139

ibasting@som.geisinger.edu | jameslbasting@gmail.com # The purpose of this script is to pull info from Medicare provider .csv # This needs to be run in the same directory as the .csv and as an "output.csv" import csv import pprint as pp #format for the csv for providers # npi,nppes_provider_last_org_name, nppes_provider_first_name, nppes_provider_city, nppes_provider_state, specialty_description, description flag, drug name, generic name, bene count, total claim count, total_30_day_fill_count, total_day_supply, total_drug_cost, bene_count_ge65, bene_count_ge65_suppress_flag, total_claim_count_ge65, ge65_suppress_flag, total_30_day_fill_count_ge65, total_day_supply_ge65, total_drug_cost_ge65 file name = "Medicare Provider Utilization and Payment Data 2018 Part D Prescriber.c sv" $table_width = 0$ In count = 0all data = $\{\}$ $state_ls = ['AE',$ 'AL', 'AK', 'AP', 'AZ', 'AR', 'CA', 'CO', 'CT', 'DC', 'DE', 'FL', 'GA', 'GU', 'HI', 'ID'. 'IL', 'IN', 'ΙΑ', 'KS', 'KY', 'LA', 'ME', 'MD', 'MA', 'Μl',

'MN', 'MS', 'MO', 'MT', 'NE', 'NV', 'NH', 'NJ', 'NM', 'NY', 'NC'. 'ND', 'OH', 'OK', 'OR', 'PA', 'PR', 'RI', 'SC', 'SD', 'TN'. 'TX', 'UT', 'VT', 'VA', 'VI', 'WA', 'WV'. 'WI', 'WY', 'XX', 'ZZ'] header = ["npi", "provider Iname", "provider_fname", "provider_city", "provider state", "spec_desc", "desc_flag", "drug_name", "generic_name", "bene_count", "total_claim_count", "total_30_day_fill_count", "total_day_supply", "total_drug_cost", "bene_count_ge65", "bene_count_ge65_suppress_flag", "total_claim_count_ge65", "ge65_suppress_flag", "total_30_day_fill_count_ge65",

```
"total day supply ge65",
"total_drug_cost_ge65"]
# default encoding (UTF-8) throws an error - have to use ISO
# Source has some nonstandard characters
with open(file name, newline=", encoding='ISO 8859-1') as csvfile:
dialect = csv.Sniffer().sniff(csvfile.read(1024))
csvfile.seek(0)
tempreader = csv.reader(csvfile, dialect)
#make the template row using the cols from above
template_output = {}
for col in header:
template output[col] = "
for row in tempreader:
if In count == 0:
#This is just to process the header
table_width = len(row)
In_count += 1
else:
i = 0
temp row = \{\}
for col in header:
temp_row[col] = row[i]
i += 1
all data[In count] = temp row
In count += 1
# all rows are in all_data now
# essentially it's the csv put into a python dict
#Get a list of unique providers so we can iterate through later
unique provider = []
for state in state Is:
for In in all data:
if all_data[ln]['spec_desc'] not in unique_provider:
unique_provider.append(all_data[ln]['spec_desc'])
else:
pass
#pp.pprint(unique_provider)
# Get totals for each specialty
num_providers = {} # {Family Practice: #, ...}
for provider in unique_provider:
num_providers[provider] = 0
used npi = []
for In in all data:
if all data[ln]['npi'] not in used npi:
num_providers[all_data[ln]['spec_desc']] += 1
used_npi.append(all_data[ln]['npi'])
else:
pass
pp.pprint(num_providers)
input()
```

```
# Broad scope looking at each provider perscribing as percent of total
spec_prescribing_output = {}
for spec in unique_provider:
spec_prescribing_output[spec] = 0
for In in all data:
temp claim count = all data[ln]["total claim count"]
temp claim count = temp claim count.replace(',',") #removed commas
ex. 1.800 -> 1800
spec_prescribing_output[all_data[ln]["spec_desc"]] +=
int(temp_claim_count)
pp.pprint(spec_prescribing_output)
input()
progress counter = 0
state data = {} # ex. {PA:{spec1:claims,spec2:claims, ... total:claims}}
for state in state Is:
state_data[state] = {}
#build out list of provider types for each state
for provider in unique_provider:
state_data[state][provider] = 0
#tabulate total claims for each state
for In in all data:
temp claim count = 0
temp_claim_count = all_data[ln]["total_claim_count"]
temp_claim_count = temp_claim_count.replace(',',") #removed commas
ex. 1,800 -> 1800
state_data[all_data[ln]["provider_state"]][all_data[ln]["spec_desc"]]
+= int(temp claim count)
progress counter += 1
if progress counter \% 1000 == 0:
print(progress_counter)
#uncomment this if necessary - takes a while
#get number of providers per state
state num providers = {} # {'PA':100, 'CT': 50, ...}
for state in state data:
state_num_providers[state] = 0
used npi = []
for In in all_data:
if all_data[ln]['npi'] not in used_npi:
state_num_providers[all_data[ln]['provider_state']] += 1
used_npi.append(int(all_data[ln]['npi']))
else:
pass
pp.pprint(state_num_providers)
with open('output.csv', mode='w') as csv_file:
csv_writer = csv.writer(csv_file, delimiter=',')
state total = 0
for state in state_data.keys():
state total = 0
```

```
for specialty in state_data[state]:
state_total += state_data[state][specialty]
csv_writer.writerow([state, specialty,
state_data[state][specialty]])
csv_writer.writerow([state, state + ' total', state_total])
print(state total)
print("done")
npi = row[0]
provider Iname = row[1]
provider_fname = row[2]
state = row[3]
spec = row[4]
desc flag = row[5]
trade_name = row[6]
generic_name = row[7]
bene_count = row[8]
total_claim_count = row[9]
total_30_day_fill_count = row[10]
total day supply = row[11
total\_drug\_cost = row[12]
bene_count_ge65 = row[13]
bene_count_ge65_suppress_flag = row[14]
total_claim_count_ge65 = row[15]
ge65_suppress_flag = row[16]
total_30_day_fill_count_ge65 = row[17]
total_day_supply_ge65 = row[18]
total\_drug\_cost\_ge65 = row[19]
```